Elanix Biotechnologies AG (FRA:ELN) EBIT per Share : €-0.46 (TTM As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG EBIT per Share?

Elanix Biotechnologies AG's EBIT per Share for the six months ended in Dec. 2018 was €-0.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2018 was €-0.46.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Elanix Biotechnologies AG's EBIT per Share or its related term are showing as below:

FRA:ELN's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Elanix Biotechnologies AG's EBIT for the six months ended in Dec. 2018 was €-0.68 Mil.

Elanix Biotechnologies AG EBIT per Share Historical Data

The historical data trend for Elanix Biotechnologies AG's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG EBIT per Share Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EBIT per Share

Get a 7-Day Free Trial

-0.03

-0.55

-0.44

-0.53

-0.46

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
EBIT per Share	Get a 7-Day Free Trial															-0.26	-0.30	-0.22	-0.37	-0.09

Elanix Biotechnologies AG EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Elanix Biotechnologies AG's EBIT per Share for the fiscal year that ended in Dec. 2018 is calculated as

	EBIT per Share		(A: Dec. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.458	/	7.541
=	-0.46

Elanix Biotechnologies AG's EBIT per Share for the quarter that ended in Dec. 2018 is calculated as

	EBIT per Share		(Q: Dec. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.675	/	7.452
=	-0.09

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.46

Elanix Biotechnologies AG (FRA:ELN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Elanix Biotechnologies AG EBIT per Share Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines